I agree this is "knock your socks off" data, but not because 65 patients met or exceeded the 6 month survival mark. The number 65 is all patients in the "current and previous clinical studies." It was only 100% of the patients in this dosimetry study that met or exceeded six months.
Does anyone know how many patients were in the "first two cohorts" of this dosimetry study?
For me, what makes it such amazing data is that these were all patients with RECURRENT GBM. If it does this well in "recurrent" patients who are on death row, imagine how much better it will do in newly diagnosed patients.
Note the "About Cotara" paragraph: "In this study, 25% of 28 RECURRENT patients survived for more than a year." That means one-quarter of these death-row patients survived MORE THAN TWICE AS LONG as these very sick patients usually survive.
... and the others who were not so lucky to survive that long were no worse off for taking a shot at it because Cotara is SO DARN SAFE. That's the really big news today. The survival data from the older Cotara studies was already off the charts, but there remained a safety/dosimetry question-- were the other patients who didn't survive so long exposed to any serious risks by taking a one-in-four shot at doubling their survival time?
If 25% of RECURRENT patients double the normal GBM survival time, my guess is that this percent will grow to at least 50% in healthier, newly-diagnosed patients.
WE WILL SEE A BIG PHARMA COTARA LICENSE VERY SOON !!! :) :)
News 
Market Data 
Discover 
